Pediatric RSV Vaccine Safety Casts A ‘Long Shadow’ For US FDA

The US FDA faces many communications challenges with vaccine skepticism rampant. Is doing everything right going to be good enough?

The VRBPAC's message that safeguards were effective in pediatric vaccine trials may not be the last word on the subject. (Shutterstock)
Michael McCaughan

Read more by Michael McCaughan

Michael McCaughan is a founding member of Prevision Policy LLC, a leading provider of regulatory and reimbursement policy analysis for the biopharma industry. He was previously the Editor-In-Chief of The Pink Sheet and remains a contributor to the publication.

More from Vaccines

More from Pathways & Standards